Log In
BCIQ
Print this Print this
 

Metozolv ODT, metoclopramide (formerly Zydis)

  Manage Alerts
Collapse Summary General Information
Company Wilmington Pharmaceuticals
DescriptionOrally disintegrating tablet formulation of metoclopramide
Molecular Target Dopamine receptor
Mechanism of ActionDopamine receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationGastroesophageal reflux disease (GERD)
Indication DetailsTreat gastroesophageal reflux disease (GERD) in adult patients who fail to respond to conventional therapy and acute and recurrent diabetic gastroparesis stasis
Regulatory Designation
PartnerValeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$12,524.0M

$11,689.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/01/2015

$11,400.0M

$11,400.0M

0

03/11/2015

$1,124.0M

$289.0M

0

Get a free BioCentury trial today